GSK executives acquire shares by reinvesting dividends

The entries distinguish London Stock Exchange ordinary-share transactions from New York Stock Exchange ADS transactions, and list different transaction dates and prices.

Rhea-AI Filing Summary

GSK plc reported dividend-reinvestment acquisitions of ordinary shares and American Depositary Shares by people identified as persons discharging managerial responsibilities or persons closely associated with them.

Ordinary-share transactions were reported at £17.5904 on October 8, 2026, following dividends paid that day. American Depositary Share transactions were reported at $46.5883 on October 9, 2026, following dividends paid on October 8. The ordinary-share transactions list the London Stock Exchange, while the ADS transactions list the New York Stock Exchange.

Key Figures

Ordinary-share transaction price: £17.5904 per ordinary share ADS transaction price: $46.5883 per ADS Ordinary shares acquired: 6,532.657 shares +5 more

8 metrics

Ordinary-share transaction price £17.5904 per ordinary share Transactions reported October 8, 2026

ADS transaction price $46.5883 per ADS Transactions reported October 9, 2026

Ordinary shares acquired 6,532.657 shares David Redfern, President Corporate Development; October 8, 2026

Ordinary shares acquired 2,999.067 shares Regis Simard, President, Global Supply Chain; October 8, 2026

Ordinary shares acquired 1.100 shares Mike Crichton, President, International; October 8, 2026

ADSs acquired 412 ADSs Charles Bancroft, Senior Independent Non-Executive Director; October 9, 2026

ADSs acquired 136 ADSs Dr Vishal Sikka, Independent Non-Executive Director; October 9, 2026

ADSs acquired 27 ADSs Dr Jeannie Lee, Independent Non-Executive Director; October 9, 2026

Key Terms

PDMR, PCA, American Depositary Shares, re-investment of dividends

4 terms

PDMR regulatory

"Details of PDMR/person closely associated"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

PCA regulatory

"person closely associated with them (‘PCA’)"

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

re-investment of dividends financial

"following the re-investment of dividends paid to shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which GSK officers and associated persons acquired ordinary shares?

The reported ordinary-share acquisitions on October 8, 2026, were: Luke Miels, Chief Executive Officer, 23.331 shares; Lynn Baxter, President, Europe, 297.818; Mike Crichton, President, International, 1.100; James Ford, SVP and Group General Counsel, Legal and Compliance, 2,014.345; Nina Mojas, President, Global Product Strategy, 246.181; Roanne Parry, Chief People Officer, 1.400; David Redfern, President Corporate Development, 6,532.657; Regis Simard, President, Global Supply Chain, 2,999.067; Philip Thomson, President, Global Affairs, 2,707.449; Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health, GSK, 1,204.461; Tony Wood, Chief Scientific Officer, 2,558.851; Neil Falkingham, PCA of Lynn Baxter, 169.615; and Kate Thomson, PCA of Philip Thomson, 112.233.

Which GSK directors acquired ADSs?

The reported American Depositary Share acquisitions on October 9, 2026, were: Elizabeth McKee Anderson, Independent Non-Executive Director, 41 ADSs; Charles Bancroft, Senior Independent Non-Executive Director, 412; Dr Hal Barron, Non-Executive Director, 32; Dr Anne Beal, Independent Non-Executive Director, 47; Dr Harry Dietz, Independent Non-Executive Director, 45; Dr Jeannie Lee, Independent Non-Executive Director, 27; and Dr Vishal Sikka, Independent Non-Executive Director, 136.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 11:13 AM EDT Accepted by SEC EDGAR 10/13/2026 - 11:12 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	23.331
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	297.818
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Mike Crichton
b)	Position/status	President, International
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	1.100
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	2,014.345
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Nina Mojas
b)	Position/status	President, Global Product Strategy
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	246.181
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Roanne Parry
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	1.400
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	6,532.657
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	2,999.067
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	2,707.449
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	1,204.461
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	2,558.851
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	169.615
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Kate Thomson
b)	Position/status	PCA of Philip Thomson (President, Global Affairs)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.5904	112.233
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-08
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Elizabeth McKee Anderson
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5883	41
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Charles Bancroft
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5883	412
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5883	32
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Anne Beal
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5883	47
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Harry Dietz
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5883	45
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Jeannie Lee
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5883	27
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Dr Vishal Sikka
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5883	136
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-10-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: October 13, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc